Can Platelet-Rich plasma boost microneedling for skin amyloidosis?
NCT ID NCT07360860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding platelet-rich plasma (PRP) to microneedling improves itching and dark patches in macular amyloidosis better than microneedling alone. Thirty adults with the condition will have each side of their face treated differently, and results will be checked with photos, skin microscopy, and patient satisfaction surveys. The goal is to see if the combination offers a safe, more effective option for this stubborn skin condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Platelet-rich plasma (PRP)
- What this could lead to
- If it works, this could offer a more effective way to reduce itching and skin darkening in people with macular amyloidosis.
- What could go wrong
- This is a very small, early study with only 30 people, so results may not apply to everyone. The improvement may be modest or no better than microneedling alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: • Both genders were included. * Patients above 18 years old. * Patients diagnosed by macular amyloidosis, proved by dermoscopy and histopathology. Exclusion Criteria: • Prior use of topical therapies in the previous 4 weeks. * Prior use of any procedures such as chemical peel or laser treatment in the previous 1 month. * Prior use of any systemic treatment for macular amyloidosis in the past 12 weeks. * Patients with other skin conditions (e.g., psoriasis, eczema). * Immunocompromised patients (HIV, chemotherapy). * Patients with history of any type of autoimmune disorders, coagulopathies, and keloid tendency. * Known or suspected allergy to ingredients
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Macular amyloidosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.